The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global polycystic ovarian syndrome treatment market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Polycystic ovarian syndrome (PCOS) refers to a hormonal disorder that leads to the abnormal and excessive production of male hormones in females. It is characterized by hyperandrogenism, ovulatory dysfunction and the development of polycystic ovaries. The disorder can also cause acne, darkening of the skin, weight gain and missed or irregular menstrual cycles, leading to infertility and development of cysts or small fluid-filled sacs in the ovaries. Some of the commonly used treatment methods for regulating and managing PCOS include oral contraceptives, antiandrogens, insulin-sensitizing agents, antidepressants and anti-obesity medicines, along with various surgical procedures, such as ovarian wedge resection and laparoscopic ovarian drilling.
The increasing prevalence of PCOS across the globe represents one of the key factors driving the growth of the market. Furthermore, rising health consciousness and increasing awareness regarding the available treatment alternatives for PCOS are also driving the market growth. PCOS often leads to hirsutism, obesity, diabetes, infertility and other chronic ailments, which has enhanced the requirement for effective treatment alternatives to manage the disease efficiently. In line with this, widespread adoption of laparoscopic ovarian drilling, which involves the surgical triggering of ovulation in women, as an effective treatment for PCOS, is also contributing to the market growth. Additionally, various technological advancements, such as the development of improved pharmacological agents, including androgen suppressors and peripheral androgen blockers, are also favoring the market growth. Other factors, including rising healthcare expenditure of the individuals, along with extensive research and development (R&D) activities, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global polycystic ovarian syndrome treatment market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, drug class, surgery type and distribution channel.
Breakup by Drug Class:
Breakup by Surgery Type:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Company, Ferring B.V., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd.
|Base Year of the Analysis||2020|
|Segment Coverage||Drug Class, Surgery Type, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Company, Ferring B.V., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at